The deal successfully concludes a research collaboration between LifeArc, Oxford University’s Nuffield Department of Clinical Neurosciences and Daiichi Sankyo.
News
Trial results show promise for chemo-free future treatment
95% of those treated in the study were found to have a complete remission rate.
‘Landmark’ day for Akcea as NICE recommends Tegsedi in rare inherited hATTR
The decision will allow patients in England with the rare, inherited, severely debilitating and fatal disease to access the treatment on the NHS.
Novartis’ wet AMD drug gets FDA filing
The decision is primarily based on Phase III data from the HAWK and HARRIER trials.
Less than 3 weeks left until the Clinical Researcher of the Year – The Americas gala dinner & awards ceremony
The PharmaTimes Clinical Researcher of the Year – The Americas gala dinner & awards ceremony will be taking place at the Sheraton Hotel in Boston on 4th May.
Genomics England completes first phase of liquid biopsy study
The results will enable researchers to perform an objective technology evaluation of the various market offerings in liquid biopsy in the second stage.
AI could identify existing drugs to help treat eye disease
The research identified seven existing drugs – either already in development or being used to treat other conditions.
Enesi and BARDA to co-develop flu vaccines
The public-private partnership aims to provide a cost-effective technological innovation.
New digital tool helps relieve pressure on NHS
Over 6,250 care homes have already signed up to the system, which is accessible on any device.
‘Half a million’ GP hours freed for patients
The three-year extension is part of a £30 million investment in a national programme for General Practice Development.
FDA approves first targeted therapy for metastatic bladder cancer
The decision was based on a clinical trial showing an objective response rate of 32.2%.
BMS, Celgene shareholders back mega merger
The decision was won by a majority of more than 75%.
AZ finds lack of lung cancer info available for patients
Available information is often outdated and sometimes inaccurate.
Data show J&J’s Invokana may slow or prevent CKD in diabetes patients
The data provides the first significant update in nearly 20 years regarding slowing the progression of CKD in patients with type II diabetes.
EMA recommends temporarily restricting Lemtrada use in MS
The review comes following new reports of immune-mediated conditions.
